[除了并发症:CAR-T作为患有二线DLBCL的脆弱患者的安全有效选择.]
1Uoc Ematologia e Trapianto di Cellule Staminali Emopoietiche, Dipartimento di Scienze di Laboratorio ed Ematologiche, Fondazione Policlinico Universitario A. Gemelli Irccs, Roma.
Recenti progressi in medicina
|February 20, 2026
概括
CD19 CAR-T疗法对患有扩散性大B细胞淋巴瘤 (DLBCL) 的脆弱患者可能是安全的. 这份病例报告显示,一名74岁的老人获得了可控毒性缓解,挑战了排除标准.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 血液学 血液学 血液学
背景情况:
- CD19 CAR-T疗法是复发性/耐药性扩散性大B细胞淋巴瘤 (DLBCL) 的标准第二线治疗方法.
- 由于毒性和非复发性死亡风险,接受CAR-T治疗的DLBCL虚弱患者的管理受到争论.
研究的目的:
- 评估axicabtagene ciloleucel的安全性和有效性,用于患有高风险DLBCL的脆弱,老年患者.
- 在CAR-T治疗中评估并发症评分与动态参数对毒性的预测值.
主要方法:
- 一名74岁的男性患有耐火性DLBCL和多种并发症,接受了Axicabtagene ciloleucel治疗的病例报告.
- 对不良事件的监测,包括细胞因子释放综合征 (CRS) 和细胞衰减.
- 使用基线并发症指数 (CIRS,HCT-CI) 和动态参数 (ECOG,MEASIX,CAR-HEMATOTOX) 评估患者的风险.
主要成果:
- 患者在治疗后14个月实现了持久的完全缓解.
- 尽管基线并发症得分很高,但该患者仅出现1级CRS,用托西利祖马布成功管理和过渡性细胞衰退.
- 仅仅伴随性疾病并不能预测严重的毒性,与ALYCANTE和现实世界队列的发现保持一致.
结论:
- 患有DLBCL的脆弱患者可以耐受CD19 CAR-T治疗,实现持久的缓解.
- 动态临床参数 (ECOG,mEASIX,CAR-HEMATOTOX) 在识别患有严重毒性风险的患者方面比静态并发症得分更有效.
- 对老年患者或并发病患者的先验排除可能会限制获得潜在的治愈性CAR-T疗法的机会.
更多相关视频
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.0K
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
1.5K
相关概念视频
Targeted Cancer Therapies
7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.0K
Treatment Resistant Cancers
2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Tumor Immunotherapy
2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
